{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=22&q=triple-negative",
    "query": {
      "q": "triple-negative",
      "condition": "Breast Cancer",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 833,
    "total_pages": 84,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=23&q=triple-negative&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=21&q=triple-negative&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T11:35:03.397Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05037825",
      "title": "The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non-Small-Cell Lung Carcinoma",
        "Malignant Melanoma",
        "Renal Cell Carcinoma",
        "Triple-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Checkpoint Inhibitor, Immune",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VastBiome",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 800,
      "start_date": "2021-11-22",
      "completion_date": "2028-09-14",
      "has_results": false,
      "last_update_posted_date": "2022-04-27",
      "last_synced_at": "2026-10-14T11:35:03.397Z",
      "location_count": 1,
      "location_summary": "Elizabethtown, Kentucky",
      "locations": [
        {
          "city": "Elizabethtown",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05037825"
    },
    {
      "nct_id": "NCT03981705",
      "title": "Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "TN ER-/PR-/HER2- Breast Cancer",
        "Triple Negative Breast Cancer",
        "HER2-positive Breast Cancer",
        "ERany/PRany/HER2+ Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Standard Trimodality Breast Imaging",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 8,
      "start_date": "2019-08-08",
      "completion_date": "2024-11-26",
      "has_results": false,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-10-14T11:35:03.397Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03981705"
    },
    {
      "nct_id": "NCT02676986",
      "title": "Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Breast Cancer ER+ve",
        "Primary Breast Cancer AR+ve TNBN"
      ],
      "interventions": [
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Queen Mary University of London",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 221,
      "start_date": "2015-08-10",
      "completion_date": "2016-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-07-05",
      "last_synced_at": "2026-10-14T11:35:03.397Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02676986"
    },
    {
      "nct_id": "NCT03719326",
      "title": "A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "TNBC - Triple-Negative Breast Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Etrumadenant",
          "type": "DRUG"
        },
        {
          "name": "IPI-549",
          "type": "DRUG"
        },
        {
          "name": "Pegylated liposomal doxorubicin (PLD)",
          "type": "DRUG"
        },
        {
          "name": "nanoparticle albumin-bound paclitaxel (NP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arcus Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 35,
      "start_date": "2018-10-15",
      "completion_date": "2021-07-02",
      "has_results": false,
      "last_update_posted_date": "2024-05-24",
      "last_synced_at": "2026-10-14T11:35:03.397Z",
      "location_count": 20,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03719326"
    },
    {
      "nct_id": "NCT07517198",
      "title": "Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Small Cell Lung Cancer (SCLC)",
        "High Grade Neuroendocrine Cancer",
        "Small Cell Carcinomas of Non-lung Origin",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Prostate Cancer",
        "Ovarian Cancer",
        "Renal Carcinoma (Clear and Non-clear Cell)",
        "Head and Neck Squamous Cell Carcinoma (HNSCC)",
        "Hepatic Cancer",
        "Gastric Cancer",
        "Triple-negative Breast Cancer (TNBC)"
      ],
      "interventions": [
        {
          "name": "EXS74539",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2026-04-13",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-10-14T11:35:03.397Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Fort Worth, Texas • West Valley City, Utah",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        },
        {
          "city": "West Valley City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07517198"
    },
    {
      "nct_id": "NCT04348916",
      "title": "Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Melanoma",
        "Solid Tumor",
        "Squamous Cell Carcinoma of Head and Neck",
        "Breast Cancer",
        "Advanced Solid Tumor",
        "Triple Negative Breast Cancer",
        "Colorectal Carcinoma",
        "Non-melanoma Skin Cancer",
        "Liver Metastases"
      ],
      "interventions": [
        {
          "name": "ONCR-177",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Oncorus, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2020-05-20",
      "completion_date": "2023-05-31",
      "has_results": false,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-10-14T11:35:03.397Z",
      "location_count": 10,
      "location_summary": "Duarte, California • Denver, Colorado • Tampa, Florida + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04348916"
    },
    {
      "nct_id": "NCT01931163",
      "title": "NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jenny C. Chang, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2013-07",
      "completion_date": "2019-01",
      "has_results": true,
      "last_update_posted_date": "2021-07-20",
      "last_synced_at": "2026-10-14T11:35:03.397Z",
      "location_count": 3,
      "location_summary": "Houston, Texas • Sugar Land, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Sugar Land",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01931163"
    },
    {
      "nct_id": "NCT06586047",
      "title": "Breast Cancer PSMA PET",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "PET imaging",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Ahmad Shariftabrizi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 90 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2024-08-29",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-14T11:35:03.397Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06586047"
    },
    {
      "nct_id": "NCT01091454",
      "title": "Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple-negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "brostallicin",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2010-06",
      "completion_date": "2014-11-01",
      "has_results": true,
      "last_update_posted_date": "2018-05-08",
      "last_synced_at": "2026-10-14T11:35:03.397Z",
      "location_count": 266,
      "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 170 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01091454"
    },
    {
      "nct_id": "NCT07015853",
      "title": "ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "TNBC - Triple-Negative Breast Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Axatilimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Stephen Shiao",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2026-06",
      "completion_date": "2033-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-10-14T11:35:03.397Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07015853"
    }
  ]
}